Domača stran2269 • HKG
add
WuXi Biologics (Cayman) Inc
Prejšnji trg. dan.
14,14 $
Dnevni razpon
14,20 $ - 15,06 $
Letni razpon
12,42 $ - 52,45 $
Tržna kapitalizacija
61,77 mrd. HKD
Povprečni obseg
53,41 mio.
Razm. P/E
17,14
Dividendna donosnost
-
Primarna borza
HKG
V novicah
Finančni podatki
Izkaz poslovnega izida
Prihodek
Čisti dohodek
| (CNY) | dec. 2023info | Sprememba L/L |
|---|---|---|
Prihodek | 4,27 mrd. | 5,95 % |
Stroški poslovanja | 818,44 mio. | 13,31 % |
Čisti dohodek | 566,53 mio. | −39,90 % |
Čista dobičkovnost prihodkov | 13,26 | −43,28 % |
Earnings per share | — | — |
EBITDA | 1,06 mrd. | −1,78 % |
Efektivna davčna stopnja | 25,05 % | — |
Bilanca stanja
Skupna sredstva
Skupne obveznosti
| (CNY) | dec. 2023info | Sprememba L/L |
|---|---|---|
Denar. in kratkor. naložbe | 11,24 mrd. | 29,02 % |
Skupna sredstva | 56,58 mrd. | 14,15 % |
Skupne obveznosti | 12,56 mrd. | −5,94 % |
Celoten lastniški kapital | 44,02 mrd. | — |
Shares outstanding | 4,22 mrd. | — |
Razmerje P/B | 1,48 | — |
Donosnost sredstev | 3,60 % | — |
Donosnost kapitala | 4,19 % | — |
Denarni tok
Neto sprememba denarnih sredstev
| (CNY) | dec. 2023info | Sprememba L/L |
|---|---|---|
Čisti dohodek | 566,53 mio. | −39,90 % |
Denar iz dejavnosti | — | — |
Denar iz naložb | — | — |
Denar iz financiranja | — | — |
Neto sprememba denarnih sredstev | — | — |
Prost denarni tok | — | — |
Vizitka
WuXi Biologics is a global Contract Research Development and Manufacturing Organization that provides open-access, integrated technology platforms for biologics drug development.
WuXi Biologics' roots date back to 2010, and began building out capabilities and facilities required for biologics discovery, development and GMP manufacturing. WuXi Biologics went public on the Hong Kong Stock Exchange in June 2017.
As of 2021, WuXi Biologics has 18 manufacturing sites including ten in China, three in the United States, two in Ireland, two in Germany, and one in Singapore.
In August 2020, WuXi Biologics was selected to become a component of the Hang Seng Index in Hong Kong.
In January 2024, WuXi Biologics' share price fell on news that the United States Congress had introduced legislation to block any federal government contracts with the company due to national security concerns. The concerns stem from allegations, denied by the company, that it has worked closely with the People's Liberation Army as a part of the Chinese Communist Party's military-civil fusion strategy. Wikipedia
Generalni direktor
Datum ustanovitve
2010
Spletno mesto
Zaposleni
12.740
